Esophagus Test TissueCypher® Receives NY State Approval, Announces Castle Biosciences

Esophagus Test TissueCypher® Receives NY State Approval, Announces Castle Biosciences Castle Biosciences, Inc. (Nasdaq: CSTL), a leading company in providing innovative tests to guide patient care, has announced that its TissueCypher® Barrett’s Esophagus test has been approved by the New…

Read MoreEsophagus Test TissueCypher® Receives NY State Approval, Announces Castle Biosciences

Therapies: PharmaEssentia Ensures Reliable Interferon Access

Therapies: PharmaEssentia Ensures Reliable Interferon Access PharmaEssentia (TWSE: 6446), a leading global biopharmaceutical company, has reaffirmed its commitment to ensuring robust and reliable access to critical interferon therapies, particularly in light of the reported global shortage of Pegasys® (peginterferon alfa-2a).…

Read MoreTherapies: PharmaEssentia Ensures Reliable Interferon Access

Voom CEO Dr. Neal Blitz Guest Edits January 2025 Clinics in Podiatric Medicine Issue on MIS

Voom CEO Dr. Neal Blitz Guest Edits January 2025 Clinics in Podiatric Medicine Issue on MIS Voom™ Medical Devices, Inc. (“Voom”), a pioneering company revolutionizing minimally invasive foot and ankle surgery, is excited to announce that its Founder and CEO,…

Read MoreVoom CEO Dr. Neal Blitz Guest Edits January 2025 Clinics in Podiatric Medicine Issue on MIS